| 1 |
A Multipurpose First-in-Human Study With the Novel CXCR7 Antagonist ACT-1004-1239 Using CXCL12 Plasma Concentrations as Target Engagement Biomarker |
|
| | Christine Huynh, Andrea Henrich, Daniel S. Strasser, Marie-Laure Boof, Mohamed Al-Ibrahim, Henriette E. Meyer Zu Schwabedissen, Jasper Dingemanse, Mike Ufer | | | Clinical Pharmacology & Therapeutics. 2021; 109(6): 1648 | | | [Pubmed] [Google Scholar] [DOI] | | | 2 |
Healthy volunteers in first-in-human oncology drug development for small molecules |
|
| | Begoña de las Heras, Dalila Bouyoucef-Cherchalli, Lesley Reeve, Andreas Reichl, Debra Mandarino, Stephen Flach, Laura Vidal, Emilie M. J. van Brummelen, Neeltje Steeghs | | | British Journal of Clinical Pharmacology. 2021; | | | [Pubmed] [Google Scholar] [DOI] | | | 3 |
A Clinical Review of Biosimilars Approved in Oncology |
|
| | Dat Ngo, Jason Chen | | | Annals of Pharmacotherapy. 2021; 55(3): 362 | | | [Pubmed] [Google Scholar] [DOI] | | | 4 |
Unveiling changes in the landscape of patient populations in cancer early drug development |
|
| | Cinta Hierro, Analía Azaro, Guillem Argilés, Elena Elez, Patricia Gómez, Joan Carles, Jordi Rodon | | | Oncotarget. 2017; 8(8): 14158 | | | [Pubmed] [Google Scholar] [DOI] | |
|
